STAAR lands new FDA panel date, Japanese approval for implantable lenses

March 4, 2014 by Arezu Sarvestani

STAAR Surgical notches regulatory milestones for its Visian Implantable Collamer Lenses, landing a rescheduled date with a panel of FDA advisors and winning Japanese approval for a new model.

STAAR lands FDA panel date, Japanese approval for implantable lenses

California ophthalmic devices maker STAAR Surgical (NSDQ:STAA) touted a pair of regulatory wins, landing a date with an FDA advisory panel and notching new Japanese market approval for its Visian Implantable Collamer Lens with CentraFLOW technology.

STAAR will meet next week with the FDA's Ophthalmic Devices Panel to review the premarket approval application for the company's Visian Toric ICL for treatment of myopic astigmatism. The original meeting, scheduled for February 14, was postponed over weather concerns.

Sign up to get our free newsletters delivered right to your inbox.

Next week's panel will discuss safety and efficacy data on the Visian Toric ICL, addressing FDA concerns about a series of deviations from the protocol for the study used to back the PMA bid.

The agency issued a warning letter in April 2004 after an inspection of a plant in Monrovia in December 2003 cited STAAR for "failure to obtain FDA approval prior to initiating a study, failure to ensure continuing Institutional Review Board (IRB) review and approval, failure to obtain signed Investigator Agreements from participating investigators, and failure to provide participating Clinical Investigators with all the information required to perform the study," according to the pre-meeting materials.